Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-04-27 |
Resource Citation "153881" Version "1" Updated "2023-08-10 21:44:41+0000"
url: https://fevir.net/resources/Citation/153881
identifier: FEvIR Object Identifier/153881, https://pubmed.ncbi.nlm.nih.gov/35378077
version: 1.0.0-ballot
title: Delany-Moretlwe 2022 clinical trial
status: active
date: 2024-04-27 20:42:39+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use') | Project Specific (Citation Artifact Classifier#project-specific) |
jurisdiction: World (m49.htm#001)
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2022-05-10
lastReviewDate: 2023-03-17
author: Brian S. Alper: , Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()
classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)
currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)
statusDate
activity: PubMed Pubstatus of Received (Citation Status Type#pubmed-pubstatus-received)
period: ?? --> 2022-02-27
statusDate
activity: PubMed Pubstatus of Revised (Citation Status Type#pubmed-pubstatus-revised)
period: ?? --> 2022-03-12
statusDate
activity: PubMed Pubstatus of Accepted (Citation Status Type#pubmed-pubstatus-accepted)
period: ?? --> 2022-03-14
statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2022-04-05 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2022-05-11 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2022-04-04 20:10:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/35378077,https://www.ncbi.nlm.nih.gov/pmc//PMC9077443,https://doi.org/10.1016/S0140-6736(22)00538-4, pii/S0140-6736(22)00538-4relatedIdentifier:
https://clinicaltrials.gov/NCT03164564Titles
Type Language Text Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Abstracts
Text Copyright **BACKGROUND:** Oral pre-exposure prophylaxis has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women experience considerable barriers to daily pill-taking, such as stigma, judgement, and the fear of violence. Safe and effective long-acting agents for HIV prevention are needed for women. We aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir diphosphate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women. **METHODS:** HPTN 084 was a phase 3, randomised, double-blind, double-dummy, active-controlled, superiority trial in 20 clinical research sites in seven countries in sub-Saharan Africa. Participants were eligible for enrolment if they were assigned female sex at birth, were aged 18-45 years, reported at least two episodes of vaginal intercourse in the previous 30 days, were at risk of HIV infection based on an HIV risk score, and agreed to use a long-acting reversible contraceptive method. Participants were randomly assigned (1:1) to either active cabotegravir with TDF-FTC placebo (cabotegravir group) or active TDF-FTC with cabotegravir placebo (TDF-FTC group). Study staff and participants were masked to study group allocation, with the exception of the site pharmacist who was responsible for study product preparation. Participants were prescribed 5 weeks of daily oral product followed by intramuscular injections every 8 weeks after an initial 4-week interval load, alongside daily oral pills. Participants who discontinued injections were offered open-label daily TDF-FTC for 48 weeks. The primary endpoints of the study were incident HIV infection in the intention-to-treat population, and clinical and laboratory events that were grade 2 or higher in all women who had received at least one dose of study product. This study is registered with ClinicalTrials.gov, NCT03164564. **FINDINGS:** From Nov 27, 2017, to Nov 4, 2020, we enrolled 3224 participants (1614 in the cabotegravir group and 1610 in the TDF-FTC group). Median age was 25 years (IQR 22-30); 1755 (54·7%) of 3209 had two or more partners in the preceding month. 40 incident infections were observed over 3898 person-years (HIV incidence 1·0% [95% CI 0·73-1·40]); four in the cabotegravir group (HIV incidence 0·2 cases per 100 person-years [0·06-0·52]) and 36 in the TDF-FTC group (1·85 cases per 100 person-years [1·3-2·57]; hazard ratio 0·12 [0·05-0·31]; p<0·0001; risk difference -1·6% [-1·0% to -2·3%]. In a random subset of 405 TDF-FTC participants, 812 (42·1%) of 1929 plasma samples had tenofovir concentrations consistent with daily use. Injection coverage was 93% of the total number of person-years. Adverse event rates were similar across both groups, apart from injection site reactions, which were more frequent in the cabotegravir group than in the TDF-FTC group (577 [38·0%] of 1519 vs 162 [10·7%] of 1516]) but did not result in injection discontinuation. Confirmed pregnancy incidence was 1·3 per 100 person-years (0·9-1·7); no congenital birth anomalies were reported. **INTERPRETATION:** Although both products for HIV prevention were generally safe, well tolerated, and effective, cabotegravir was superior to TDF-FTC in preventing HIV infection in women. **FUNDING:** National Institute of Allergy and Infectious Diseases, ViiV Healthcare, and the Bill & Melinda Gates Foundation. Additional support was provided through the National Institute of Mental Health, the National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. ViiV Healthcare and Gilead Sciences provided pharmaceutical support. Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. relatesTo
type: cites
citation: UNAIDS Confronting inequalities: lessons for pandemic responses from 40 years of AIDS. July 14, 2021. https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update-slideset
relatesTo
type: cites
citation: WHO . World Health Organization; Geneva: 2015. Policy brief: pre-exposure prophylaxis (PrEP): WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Celum CL, Delany-Moretlwe S, Baeten JM, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(suppl 4)
Documents
Url https://pubmed.ncbi.nlm.nih.gov/31328444/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/31328444relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Velloza J, Khoza N, Scorgie F, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23
Documents
Url https://pubmed.ncbi.nlm.nih.gov/32144874/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/32144874relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Cottrell ML, Yang KH, Prince HM, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214:55–64.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26917574/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26917574relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Andrews CD, Yueh YL, Spreen WR, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25589630/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25589630relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Radzio J, Spreen W, Yueh YL, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25589631/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25589631relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331–e340.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/28546090/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/28546090relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15
Documents
Url https://pubmed.ncbi.nlm.nih.gov/30408115/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/30408115relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595–608.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/34379922/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/34379922relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Balkus JE, Brown E, Palanee T, et al. An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. 2016;72:333–343.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26918545/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26918545relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Eshleman SH, Fogel JM, Piwowar-Manning E, et al. Characterization of HIV infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis (in press).
Documents
Url https://pubmed.ncbi.nlm.nih.gov/35301540/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/35301540relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384–390.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22935078/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22935078relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2017;62:e01710–e01717.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/29038282/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/29038282relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066) AIDS Res Hum Retroviruses. 2016;32:32–43.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26414912/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26414912relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–348.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24784763/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24784763relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Marzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224:1581–1592.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/33740057/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/33740057relatesTo
type: cites
citation: US Department of Health and Human Services Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. July, 2017. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
relatesTo
type: cites
citation: Emerson SS, Fleming TR. Parameter estimation following group sequential hypothesis testing. Biometrika. 1990;77:875–892.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384:1003–1014.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/33730454/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/33730454relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gray GE, Bekker LG, Laher F, et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N Engl J Med. 2021;384:1089–1100.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/33761206/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/33761206relatesTo
type: cites
citation: Palanee-Phillips T, Baeten J, Heller K, et al. HIV incidence remains high in women in South Africa: data from the ECHO trial. 10th International AIDS Society Conference on HIV Science; July 21–24, 2019 (abstr LBPEC23).
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Pillay D, Stankevitz K, Lanham M, et al. Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa. PLoS One. 2020;15
Documents
Url https://pubmed.ncbi.nlm.nih.gov/32352969/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/32352969relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Bärnighausen K, Geldsetzer P, Matse S, et al. Qualitative accounts of PrEP discontinuation from the general population in Eswatini. Cult Health Sex. 2021;23:1198–1214.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/32633617/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/32633617relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Quaife M, Eakle R, Cabrera Escobar MA, et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38:120–133.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/28863752/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/28863752relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Minnis AM, Browne EN, Boeri M, et al. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80:394–403.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/30633040/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/30633040relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Laher F, Salami T, Hornschuh S, et al. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important. BMC Public Health. 2020;20
Documents
Url https://pubmed.ncbi.nlm.nih.gov/33160341/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/33160341relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–518.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25651245/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25651245relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Baeten JM, Brown ER, Hillier SL. Dapivirine vaginal ring for HIV-1 prevention. N Engl J Med. 2017;376:995–996.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/28273023/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/28273023relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803–815.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/31339677/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/31339677relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70:319–322.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/31125395/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/31125395relatesTo
type: cites
citation: Eshleman S, Fogel JM, Halvas EK, et al. CAB-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk. 29th Conference on Retroviruses and Opportunistic Infections; Feb 12–16, 2022 (abstr Oral-08).
relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Lancet. 2022 May 7;399(10337):1754-1755
Documents
Url https://pubmed.ncbi.nlm.nih.gov/35378079/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/35378079relatesTo
type: correction-in
classifier: Published Erratum (#D016425)
citation: Lancet. 2022 May 7;399(10337):1778
Documents
Url https://pubmed.ncbi.nlm.nih.gov/35526551/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/35526551relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Med. 2022 Aug;28(8):1542-1543
Documents
Url https://pubmed.ncbi.nlm.nih.gov/35869309/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/35869309relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nature. 2022 Aug;608(7923):460-461
Documents
Url https://pubmed.ncbi.nlm.nih.gov/35931763/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/35931763relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nature. 2022 Aug;608(7922):239
Documents
Url https://pubmed.ncbi.nlm.nih.gov/35945377/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/35945377publicationForm
PublishedIns
Type Identifier Title PublisherLocation Periodical (Published In Type#D020492) Electronic ISSN Type/1474-547X, ISOAbbreviation/Lancet, ISSN Linking/0140-6736, Medline Title Abbreviation/Lancet, NLM Unique ID/2985213R Lancet (London, England) England citedMedium: Internet (Cited Medium#internet)
volume: 399
issue: 10337
articleDate: 2022-05-07
publicationDateText: 2022-May-07
language: English (Tags for the Identification of Languages#en)
pageString: 1779-1789
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2022-04-01
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Anti-HIV Agents (#D019380), Diketopiperazines (#D054659), Pyridones (#D011728), Emtricitabine (chemical-substances#G70B4ETF4S; #D000068679), cabotegravir (chemical-substances#HMH0132Z1Q; #C584914)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Adult (#D000328)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Anti-HIV Agents (#D019380)
freeToShare: true
Components
Type Classifier qualifier () is Major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Child (#D002648)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Diketopiperazines (#D054659)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Emtricitabine (#D000068679)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Female (#D005260)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: HIV Infections (#D015658)
freeToShare: true
component
type: qualifier ()
classifier: is Major topic ()
component
type: qualifier ()
classifier: chemically induced (#Q000139)
component
component
type: qualifier ()
classifier: epidemiology (#Q000453)
component
component
type: qualifier ()
classifier: prevention & control (#Q000517)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: HIV Seropositivity (#D006679)
freeToShare: true
component
type: qualifier ()
classifier: is Major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: HIV-1 (#D015497)
freeToShare: true
Components
Type Classifier qualifier () is Major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Infant, Newborn (#D007231)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Pregnancy (#D011247)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Pyridones (#D011728)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Clinical Trial, Phase III (#D017428), Journal Article (#D016428), Randomized Controlled Trial (#D016449)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
name: Sinead Delany-Moretlwe
forenameInitials: S
affiliation: : Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: sdelany@wrhi.ac.za.
entry
name: James P Hughes
forenameInitials: JP
affiliation: : Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
entry
name: Peter Bock
forenameInitials: P
affiliation: : Desmond Tutu TB Centre, University of Stellenbosch, Stellenbosch, South Africa.
entry
name: Samuel Gurrion Ouma
forenameInitials: SG
affiliation: : Kisumu Clinical Research Site, Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
entry
name: Portia Hunidzarira
forenameInitials: P
affiliation: : Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
entry
name: Dishiki Kalonji
forenameInitials: D
affiliation: : HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.
entry
name: Noel Kayange
forenameInitials: N
affiliation: : Blantyre Clinical Research Site, College of Medicine, University of Malawi, Blantyre, Malawi.
entry
name: Joseph Makhema
forenameInitials: J
affiliation: : Botswana Harvard AIDS Institute Partnership (BHP), Gaborone, Botswana.
entry
name: Patricia Mandima
forenameInitials: P
affiliation: : Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
entry
name: Carrie Mathew
forenameInitials: C
affiliation: : Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
entry
name: Elizabeth Spooner
forenameInitials: E
affiliation: : HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.
entry
name: Juliet Mpendo
forenameInitials: J
affiliation: : International AIDS Vaccine Initiative, Uganda Virus Research Institute, Entebbe, Uganda.
entry
name: Pamela Mukwekwerere
forenameInitials: P
affiliation: : Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
entry
name: Nyaradzo Mgodi
forenameInitials: N
affiliation: : Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
entry
name: Patricia Nahirya Ntege
forenameInitials: PN
affiliation: : Baylor College of Medicine Children's Foundation Uganda, Kampala, Uganda.
entry
name: Gonasagrie Nair
forenameInitials: G
affiliation: : Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa.
entry
name: Clemensia Nakabiito
forenameInitials: C
affiliation: : Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
entry
name: Harriet Nuwagaba-Biribonwoha
forenameInitials: H
affiliation: : Eswatini Prevention Center, International Center for AIDS Care and Treatment Program at Columbia University Mailman School of Public Health, New York, NY, USA.
entry
name: Ravindre Panchia
forenameInitials: R
affiliation: : Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
entry
name: Nishanta Singh
forenameInitials: N
affiliation: : HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.
entry
name: Bekezela Siziba
forenameInitials: B
affiliation: : Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
entry
name: Jennifer Farrior
forenameInitials: J
affiliation: : FHI 360, Durham, NC, USA.
entry
name: Scott Rose
forenameInitials: S
affiliation: : FHI 360, Durham, NC, USA.
entry
name: Peter L Anderson
forenameInitials: PL
affiliation: : Anschutz Medical Campus, University of Colorado, Aurora, CO, USA.
entry
name: Susan H Eshleman
forenameInitials: SH
affiliation: : Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
entry
name: Mark A Marzinke
forenameInitials: MA
affiliation: : Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
entry
name: Craig W Hendrix
forenameInitials: CW
affiliation: : Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
entry
name: Stephanie Beigel-Orme
forenameInitials: S
affiliation: : Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
entry
name: Sybil Hosek
forenameInitials: S
affiliation: : Department of Psychiatry, Stroger Hospital of Cook County, Chicago, IL, USA.
entry
name: Elizabeth Tolley
forenameInitials: E
affiliation: : FHI 360, Durham, NC, USA.
entry
name: Nirupama Sista
forenameInitials: N
affiliation: : FHI 360, Durham, NC, USA.
entry
name: Adeola Adeyeye
forenameInitials: A
affiliation: : Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
entry
name: James F Rooney
forenameInitials: JF
affiliation: : Gilead Sciences, Foster City, CA, USA.
entry
name: Alex Rinehart
forenameInitials: A
affiliation: : ViiV Healthcare, Durham, NC, USA.
entry
name: William R Spreen
forenameInitials: WR
affiliation: : ViiV Healthcare, Durham, NC, USA.
entry
name: Kimberly Smith
forenameInitials: K
affiliation: : ViiV Healthcare, Durham, NC, USA.
entry
name: Brett Hanscom
forenameInitials: B
affiliation: : Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
entry
name: Myron S Cohen
forenameInitials: MS
affiliation: : University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA.
entry
name: Mina C Hosseinipour
forenameInitials: MC
affiliation: : University of North Carolina (UNC) at Chapel Hill, Chapel Hill, NC, USA; UNC Project-Malawi, Lilongwe, Malawi.
entry
name: HPTN 084 study group
Generated Narrative: Practitioner #author0
name: Sinead Delany-Moretlwe
Generated Narrative: Practitioner #author1
name: James P Hughes
Generated Narrative: Practitioner #author2
name: Peter Bock
Generated Narrative: Practitioner #author3
name: Samuel Gurrion Ouma
Generated Narrative: Practitioner #author4
name: Portia Hunidzarira
Generated Narrative: Practitioner #author5
name: Dishiki Kalonji
Generated Narrative: Practitioner #author6
name: Noel Kayange
Generated Narrative: Practitioner #author7
name: Joseph Makhema
Generated Narrative: Practitioner #author8
name: Patricia Mandima
Generated Narrative: Practitioner #author9
name: Carrie Mathew
Generated Narrative: Practitioner #author10
name: Elizabeth Spooner
Generated Narrative: Practitioner #author11
name: Juliet Mpendo
Generated Narrative: Practitioner #author12
name: Pamela Mukwekwerere
Generated Narrative: Practitioner #author13
name: Nyaradzo Mgodi
Generated Narrative: Practitioner #author14
name: Patricia Nahirya Ntege
Generated Narrative: Practitioner #author15
name: Gonasagrie Nair
Generated Narrative: Practitioner #author16
name: Clemensia Nakabiito
Generated Narrative: Practitioner #author17
name: Harriet Nuwagaba-Biribonwoha
Generated Narrative: Practitioner #author18
name: Ravindre Panchia
Generated Narrative: Practitioner #author19
name: Nishanta Singh
Generated Narrative: Practitioner #author20
name: Bekezela Siziba
Generated Narrative: Practitioner #author21
name: Jennifer Farrior
Generated Narrative: Practitioner #author22
name: Scott Rose
Generated Narrative: Practitioner #author23
name: Peter L Anderson
Generated Narrative: Practitioner #author24
name: Susan H Eshleman
Generated Narrative: Practitioner #author25
name: Mark A Marzinke
Generated Narrative: Practitioner #author26
name: Craig W Hendrix
Generated Narrative: Practitioner #author27
name: Stephanie Beigel-Orme
Generated Narrative: Practitioner #author28
name: Sybil Hosek
Generated Narrative: Practitioner #author29
name: Elizabeth Tolley
Generated Narrative: Practitioner #author30
name: Nirupama Sista
Generated Narrative: Practitioner #author31
name: Adeola Adeyeye
Generated Narrative: Practitioner #author32
name: James F Rooney
Generated Narrative: Practitioner #author33
name: Alex Rinehart
Generated Narrative: Practitioner #author34
name: William R Spreen
Generated Narrative: Practitioner #author35
name: Kimberly Smith
Generated Narrative: Practitioner #author36
name: Brett Hanscom
Generated Narrative: Practitioner #author37
name: Myron S Cohen
Generated Narrative: Practitioner #author38
name: Mina C Hosseinipour
Generated Narrative: Organization #author39
name: HPTN 084 study group
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Adult (#D000328)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Anti-HIV Agents (#D019380)
freeToShare: true
Components
Type Classifier qualifier () is Major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Child (#D002648)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Diketopiperazines (#D054659)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Emtricitabine (#D000068679)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Female (#D005260)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: HIV Infections (#D015658)
freeToShare: true
component
type: qualifier ()
classifier: is Major topic ()
component
type: qualifier ()
classifier: chemically induced (#Q000139)
component
component
type: qualifier ()
classifier: epidemiology (#Q000453)
component
component
type: qualifier ()
classifier: prevention & control (#Q000517)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: HIV Seropositivity (#D006679)
freeToShare: true
component
type: qualifier ()
classifier: is Major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: HIV-1 (#D015497)
freeToShare: true
Components
Type Classifier qualifier () is Major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Infant, Newborn (#D007231)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Pregnancy (#D011247)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Pyridones (#D011728)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-04-27
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change